Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Business News › Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

May 20, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Personalis said today that it has signed a research agreement with FLX Bio to use its universal cancer immunogenomics ImmunoID Next platform to evaluate therapy-related changes in tumors of advanced cancer patients treated with FLX Bio's FLX475 drug.

As part of the collaboration, FLX Bio will apply the Personalis assay in a patient cohort that is part of a Phase I/II clinical trial evaluating FLX475, a CCR4 antagonist, as monotherapy or in combination with pembrolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Cancer

  1. NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths

  2. Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors

    Premium

  3. Verastem Oncology's Combination Therapy Advances in KRAS-Mutated Lung Cancer

    Premium

  4. Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

  5. AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.